Jolanta Jaśkowska

Dr. Jolanta Jaśkowska


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MKMarcin Kołaczkowski
Marcin Kołaczkowski
MMMonika Marcinkowska
Monika Marcinkowska
ABAdam Bucki
Adam Bucki
MPMaciej Pawłowski
Maciej Pawłowski
KMKatarzyna Mitka
Katarzyna Mitka
PBPrzemyslaw Bienkowski
Przemyslaw Bienkowski

30 December 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
Przemysław JodłowskiPrzemysław Jodłowski
Przemysław Jodłowski
GKGrzegorz Kurowski
Grzegorz Kurowski
ŁKŁukasz Kuterasiński
Łukasz Kuterasiński
MSMaciej Sitarz
Maciej Sitarz
PJPiotr Jeleń
Piotr Jeleń
ABAnna Boguszewska-Czubara
Anna Boguszewska-Czubara

14 June 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
Przemysław JodłowskiPrzemysław Jodłowski
Przemysław Jodłowski
KDKlaudia Dymek
Klaudia Dymek
GKGrzegorz Kurowski
Grzegorz Kurowski
Jolanta JaskowskaJolanta Jaskowska
Jolanta Jaskowska
Wojciech BuryWojciech Bury
Wojciech Bury
ABAnna Boguszewska-Czubara
Anna Boguszewska-Czubara
In this study, we present a complementary approach for obtaining an effective drug, based on acriflavine (ACF) and zirconium-based metal-organic frameworks (MOFs), against SARS-CoV-2. The experimental results showed that acriflavine inhibits the interaction between viral receptor-binding domain (RBD) of spike protein and angiotensin converting enzyme-2 (ACE2) host receptor driving viral cell entry. The prepared ACF@MOF composites exhibited low (MOF-808 and UiO-66) and high (UiO-67 and NU-1000) ACF loadings. The drug release profiles from prepared composites showed different release kinetics depending on the local pore environment. The long-term ACF release with the effective antiviral ACF concentration was observed for all studied ACF@MOF composites. The density functional theory (DFT) calculations allowed us to determine that π-π stacking together with electrostatic interaction plays an important role in acriflavine adsorption and release from ACF@MOF composites. The molecular docking results have shown that acriflavine interacts with several possible binding sites within the RBD and binding site at the RBD/ACE2 interface. The cytotoxicity and ecotoxicity results have confirmed that the prepared ACF@MOF composites may be considered potentially safe for living organisms. The complementary experimental and theoretical results presented in this study have confirmed that the ACF@MOF composites may be considered a potential candidate for the COVID-19 treatment, which makes them good candidates for clinical trials.

7 October 2010 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
PKPiotr Kowalski
Piotr Kowalski
Jolanta JaskowskaJolanta Jaskowska
Jolanta Jaskowska
ABAndrzej Bojarski
Andrzej Bojarski
BDBeata Duszyńska
Beata Duszyńska
ABAdam Bucki
Adam Bucki
MKMarcin Kołaczkowski
Marcin Kołaczkowski

23 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Jolanta JaskowskaJolanta Jaskowska
Jolanta Jaskowska
PZPrzemysław Zaręba
Przemysław Zaręba
PŚPaweł Śliwa
Paweł Śliwa
Edyta PindelskaEdyta Pindelska
Edyta Pindelska
GSGrzegorz Satała
Grzegorz Satała
ZMZbigniew Majka
Zbigniew Majka
Trazodone, a well-known antidepressant drug widely used throughout the world, works as a 5-hydroxytryptamine (5-HT2) and α1-adrenergic receptor antagonist and a serotonin reuptake inhibitor. Our research aimed to develop a new method for the synthesis of trazodone and its derivatives. In the known methods of the synthesis of trazodone and its derivatives, organic and toxic solvents are used, and the synthesis time varies from several to several dozen hours. Our research shows that trazodone and its derivatives can be successfully obtained in the presence of potassium carbonate as a reaction medium in the microwave field in a few minutes. As a result of the research work, 17 derivatives of trazodone were obtained, including compounds that exhibit the characteristics of 5-HT1A receptor ligands. Molecular modeling studies were performed to understand the differences in the activity toward 5-HT1A and 5-HT2A receptors between ligand 10a (2-(6-(4-(3-chlorophenyl)piperazin-1-yl)hexyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one) (5-HT1A Ki = 16 nM) and trazodone. The docking results indicate the lack of the binding of ligand 10a to 5-HT2AR, which is consistent with the in vitro studies. On the other hand, the docking results for the 5-HT1A receptor indicate two possible binding modes. Crystallographic studies support the hypothesis of an extended conformation.

1 September 2008 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
Jolanta JaskowskaJolanta Jaskowska
Jolanta Jaskowska
PKPiotr Kowalski
Piotr Kowalski